CureVac Historical Financial Ratios
| CVAC Stock | USD 3.00 0.11 3.81% |
CureVac NV is presently reporting on over 92 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0, PTB Ratio of 1.77 or Days Sales Outstanding of 197 will help investors to properly organize and evaluate CureVac NV financial condition quickly.
CureVac |
About CureVac Financial Ratios Analysis
CureVac NVFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate CureVac NV investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on CureVac financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across CureVac NV history.
CureVac NV Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing CureVac NV stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on CureVac NV sales, a figure that is much harder to manipulate than other CureVac NV multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Ev To Sales
The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.Inventory Turnover
A ratio showing how many times a company's inventory is sold and replaced over a period, indicating the efficiency of inventory management.Payout Ratio
Payout Ratio is the proportion of CureVac NV earnings paid out as dividends to shareholders. Payout Ratio is typically expressed as a percentage but can be shown as dividends paid out as a proportion of cash flow. The payout ratio is used to determine the sustainability of CureVac NV dividend payments. A lower payout ratio is generally preferable to a higher payout ratio, with a ratio greater than 100% indicating CureVac NV is paying out more in dividends than it makes in net income.Most ratios from CureVac NV's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into CureVac NV current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CureVac NV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade CureVac Stock refer to our How to Trade CureVac Stock guide.At present, CureVac NV's Capex To Depreciation is projected to slightly decrease based on the last few years of reporting. The current year's Days Of Inventory On Hand is expected to grow to 132.40, whereas Price To Sales Ratio is forecasted to decline to 17.07.
| 2022 | 2023 | 2024 | 2025 (projected) | Payables Turnover | 2.7 | 2.68 | 3.08 | 2.82 | Days Of Inventory On Hand | 47.59 | 72.79 | 83.71 | 132.4 |
CureVac NV fundamentals Correlations
Click cells to compare fundamentals
CureVac NV Account Relationship Matchups
High Positive Relationship
High Negative Relationship
CureVac NV fundamentals Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Price To Sales Ratio | 179.32 | 54.49 | 15.79 | 15.62 | 17.96 | 17.07 | |
| Ptb Ratio | 12.33 | 8.15 | 2.0 | 1.62 | 1.87 | 1.77 | |
| Days Sales Outstanding | 13.6 | 190.45 | 48.74 | 268.26 | 308.5 | 197.09 | |
| Book Value Per Share | 5.38 | 3.7 | 2.82 | 2.34 | 2.11 | 1.9 | |
| Free Cash Flow Yield | 0.0542 | (0.15) | (0.36) | (0.38) | (0.44) | (0.42) | |
| Operating Cash Flow Per Share | 3.95 | (3.94) | (1.51) | (1.22) | (1.4) | (1.33) | |
| Stock Based Compensation To Revenue | 1.12 | 0.29 | 0.15 | 0.14 | 0.16 | 0.28 | |
| Capex To Depreciation | 4.44 | 8.16 | 3.93 | 2.36 | 2.12 | 3.26 | |
| Pb Ratio | 12.33 | 8.15 | 2.0 | 1.62 | 1.87 | 1.77 | |
| Ev To Sales | 152.89 | 46.9 | 9.06 | 8.91 | 10.25 | 9.74 | |
| Free Cash Flow Per Share | 3.59 | (4.63) | (2.01) | (1.47) | (1.69) | (1.77) | |
| Roic | (0.0973) | (0.51) | (0.35) | (0.45) | (0.41) | (0.43) | |
| Inventory Turnover | 0.98 | 4.24 | 7.67 | 5.01 | 4.51 | 3.79 | |
| Net Income Per Share | (0.98) | (2.21) | (1.32) | (1.18) | (1.36) | (1.42) | |
| Days Of Inventory On Hand | 374.22 | 86.06 | 47.59 | 72.79 | 83.71 | 132.4 | |
| Payables Turnover | 0.8 | 1.95 | 2.7 | 2.68 | 3.08 | 2.82 | |
| Sales General And Administrative To Revenue | 0.92 | 0.85 | 1.32 | 1.41 | 1.63 | 1.56 | |
| Research And Ddevelopement To Revenue | 2.48 | 2.33 | 7.92 | 0.93 | 2.15 | 3.5 | |
| Capex To Revenue | 0.97 | 1.24 | 1.38 | 1.03 | 0.92 | 0.86 | |
| Cash Per Share | 10.02 | 4.39 | 2.65 | 1.84 | 1.65 | 2.59 | |
| Pocfratio | 16.79 | (7.66) | (3.72) | (3.13) | (2.82) | (2.96) | |
| Interest Coverage | (5.61) | (39.88) | (67.29) | (109.99) | (98.99) | (103.94) | |
| Capex To Operating Cash Flow | 0.0906 | (0.17) | (0.33) | (0.21) | (0.24) | (0.25) | |
| Pfcf Ratio | 18.46 | (6.52) | (2.81) | (2.6) | (2.34) | (2.46) | |
| Days Payables Outstanding | 453.85 | 187.35 | 135.38 | 136.08 | 156.49 | 214.12 | |
| Income Quality | (4.02) | 1.78 | 1.15 | 1.03 | 0.93 | 0.97 | |
| Roe | (0.18) | (0.6) | (0.47) | (0.5) | (0.58) | (0.61) | |
| Ev To Operating Cash Flow | 14.31 | (6.59) | (2.14) | (1.79) | (1.61) | (1.69) | |
| Pe Ratio | (67.94) | (13.63) | (4.28) | (3.23) | (2.91) | (3.05) | |
| Return On Tangible Assets | (0.0862) | (0.36) | (0.3) | (0.34) | (0.31) | (0.32) | |
| Ev To Free Cash Flow | 15.74 | (5.61) | (1.61) | (1.48) | (1.33) | (1.4) | |
| Earnings Yield | (0.0147) | (0.0734) | (0.23) | (0.31) | (0.36) | (0.34) | |
| Intangibles To Total Assets | 0.00936 | 0.0114 | 0.0369 | 0.036 | 0.0414 | 0.0342 | |
| Net Debt To E B I T D A | 10.5 | 2.02 | 2.17 | 1.54 | 1.39 | 2.14 | |
| Current Ratio | 5.61 | 2.63 | 3.74 | 2.57 | 2.31 | 2.56 | |
| Tangible Book Value Per Share | 5.27 | 3.63 | 2.65 | 2.22 | 1.99 | 1.82 | |
| Receivables Turnover | 26.84 | 1.92 | 7.49 | 1.36 | 1.56 | 1.49 | |
| Shareholders Equity Per Share | 5.38 | 3.7 | 2.82 | 2.34 | 2.11 | 1.9 | |
| Debt To Equity | 0.0423 | 0.042 | 0.0789 | 0.0809 | 0.0728 | 0.0765 | |
| Capex Per Share | 0.36 | 0.69 | 0.49 | 0.25 | 0.23 | 0.26 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CureVac NV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade CureVac Stock refer to our How to Trade CureVac Stock guide.You can also try the Stocks Directory module to find actively traded stocks across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CureVac NV. If investors know CureVac will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CureVac NV listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.51 | Revenue Per Share | Quarterly Revenue Growth 0.905 | Return On Assets | Return On Equity |
The market value of CureVac NV is measured differently than its book value, which is the value of CureVac that is recorded on the company's balance sheet. Investors also form their own opinion of CureVac NV's value that differs from its market value or its book value, called intrinsic value, which is CureVac NV's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CureVac NV's market value can be influenced by many factors that don't directly affect CureVac NV's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CureVac NV's value and its price as these two are different measures arrived at by different means. Investors typically determine if CureVac NV is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CureVac NV's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.